Prevention of invasive group A streptococcal disease among household contacts of case-patients: Is prophylaxis warranted?

JAMA

Volumn 279, Issue 15, 1998, Pages 1206-1210

  Levine, Orin S ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOPROPHYLAXIS; CONTACT EXAMINATION; COST BENEFIT ANALYSIS; DISEASE TRANSMISSION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS INFECTION; TREATMENT PLANNING;

EID: 0032522786     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.15.1206     Document Type: Review

References (49)

1. Kaplan EL. Public health implications of group A streptococcal infections in the 1990s. Pediatr Infect Dis J. 1994;13:580-583.
2. Stevens DL. Invasive group A streptococcal infections: the past, present and future. Pediatr Infect Dis J. 1994;13:561-566.
3. Hoge CW, Schwartz B, Talkington DF, Breiman RF, MacNeill EM, Englender SJ. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome: a retrospective population-based study. JAMA 1993;269:384-389.
4. Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. JAMA. 1993;269:390-391.
5. Necrotizing fasciitis. Wkly Epidemiol Rec. 1994; 69:165-166.
6. Chelsom J, Halstensen A, Haga T, Hoiby EA. Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet. 1994;344:1111-1115.
7. Bucher A, Martin PR, Hoiby EA, et al. Spectrum of disease in bacteraemic patients during a Streptococcus pyogenes serotype M-1 epidemic in Norway in 1988. Eur J Clin Microbiol Infect Dis. 1992;11: 416-426.
8. Gaworzewska E, Colman G. Changes in the pattern of infection caused by streptococcus pyogenes. Epidemiol Infect. 1988;100:257-269.
9. Centers for Disease Control and Prevention. Invasive group A streptococcal infections - United Kingdom, 1994. MMWR Morb Mortal Wkly Rep. 1994;43:401-402.
10. Colman G, Tanna A, Efstratiou A, Gaworzewska ET. The serotypes of Streptococcus pyogenes present in Britain during 1980-1990 and their association with disease. J Med Microbiol. 1993;39:165-178.
11. Davies HD, McGeer A, Schwartz B, et al. A prospective, population-based study of invasive group A streptococcal infections, includingtoxic shock syndrome and the risk of secondary invasive disease. N Engl J Med. 1996;335:547-554.
12. Centers for Disease Control. Group A beta-hemolytic streptococcal bacteremia - Colorado, 1989. MMWR Morb Mortal Wkly Rep. 1990;39:3-11.
13. O'Brien KL, Levine OS, Schwartz B. The changing epidemiology of group A Streptococcus infections. Semin Pediatr Infect Dis. 1997;8:10-16.
14. O'Brien KL, Schwartz B, Facklam RR, et al. Population based active surveillance for invasive group A Streptococcus. In: Abstracts, 37th International Conference of Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; September 1997. Abstract K159.
15. Centers for Disease Control and Prevention. Outbreak of invasive group A Streptococcus associated with varicella in a childcare center - Boston, Mass. MMWR Morb Mortal Wkly Rep. 1997;46:944-949.
16. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med. 1989;321:1-7.
17. Schwartz B, Elliott JA, Butler JC, et al. Clusters of invasive group A streptococcal infections in family, hospital, and nursing home settings. Clin Infect Dis. 1992;15:277-284.
18. Lamothe F, D'Amico P, Ghosn P, Tremblay C, Braidy J, Patenaude J. Clinical usefulness of intravenous human immunoglobulins in invasive group A streptococcal infections: case report and review. Clin Infect Dis. 1995;21:1469-1470.
19. Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Low DE. Intravenous immunoglobulin (IVIG) therapy in streptococcal toxic shock syndrome (STSS): results of a matched case-control study. In: Abstracts, 35th International Conference of Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; September 1995. Abstract LM68.
20. Schwartz B. Chemoprophylaxis for bacterial infections: principles of and application to meningococcal infections. Rev Infect Dis. 1991;13 (suppl 2): -S170-S173.
21. Schwartz B, Facklam RR, Breiman RF. Changing epidemiology of group A streptococcal infection in the USA. Lancet. 1990;336:1167-1171.
22. Johnson DR, Stevens DL, Kaplan EL. Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. J Infect Dis. 1992;166:374-382.
23. Cleary PP, Kaplan EL, Handley JP, et al. Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s. Lancet. 1992;339:518-521.
24. Talkington DF, Schwartz B, Black CM, et al. Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immunol. 1993;61:3369-3374.
25. Belani K, Schlievert PM, Kaplan EL, Ferrieri P. Association of exotoxin-producing group A streptococci and severe disease in children. Pediatr Infect Dis J. 1991;10:351-354.
26. Musser JM, Hauser AR, Kim MH, Schlievert PM, Nelson K, Selander RK. Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc Natl Acad Sci U S A. 1991;88:2668-2672.
27. McGeer A, Low DE, Davies HD, Schwartz B. Invasive group A streptococcal infections. N Engl J Med. 1997;336:514.
28. Dingle JH, Badger GF, Jordan WS. Streptococcal infections. In: Dingle JH, Badger GF, Jordan WS, eds. Illness in the Home. Cleveland, Ohio: Western Reserve University; 1964:97-117.
29. Holmstrom L, Nyman B, Rosengren M, Wallander S, Ripa T. Outbreaks of infections with erythromycin-resistant group A streptococci in child day care centres. Scand J Infect Dis. 1990;22:179-185.
30. Cockerill FR III, MacDonald KL, Thompson RL, et al. An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. JAMA. 1997;277:38-43.
31. Brundage JF, Gunzenhauser JD, Longfield JN, et al. Epidemiology and control of acute respiratory diseases with emphasis on group A beta-hemolytic streptococcus: a decade of U.S. Army experience. Pediatrics. 1996;97:964-970.
32. Schwartz B, Ussery XT. Group A streptococcal outbreaks in nursing homes. Infect Control Hosp Epidemiol. 1992;13:742-747.
33. American Academy of Pediatrics. Group A streptococcal infections. In: Peter G, ed. Red Book: Report of the Committee on Infectious Diseases. Elk Grove Village, Ill: American Academy of Pediatrics; 1997:483-493.
34. Coburn AF, Young DC. The removal of contaminated dust reservoirs. In: Epidemiology of Hemolytic Streptococcus. Baltimore, Md: Williams & Wilkins; 1949:157-169.
35. Levine OS, Turf E, Ginsberg R, et al. An outbreak of invasive group A streptococcal (GAS) disease in the Shenandoah Valley of Virginia. In: Abstracts, 35th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; September 1995. Abstract K-134.
36. Wannamaker LW, Denny FW, Perry WD, et al. The effect of penicillin prophylaxis on streptococcal disease rates and the carrier state. N Engl J Med. 1953;249:1-7.
37. Frank PF. Streptococcal prophylaxis in navy recruits with oral benzathine penicillin. US Armed Forces Med J. 1958;9:543-560.
38. Gunzenhauser JD, Brundage JF, McNeil JG, Miller RN. Broad and persistent effects of benzathine penicillin G in the prevention of febrile, acute respiratory disease. J Infect Dis. 1992;166: 365-373.
39. Ferrieri P, Dajani AS, Wannamaker LW. Benzathine penicillin in the prophylaxis of streptococcal skin infections: a pilot study. J Pediatr. 1973; 83:572-577.
40. Ferrieri P, Dajani AS, Wannamaker LW. A controlled study of penicillin prophylaxis against streptococcal impetigo. J Infect Dis. 1974;129:429-438.
41. Chaudhary S, Bilinsky SA, Hennessy JL, et al. Penicillin V and rifampin for the treatment of group A streptococeal pharyngitis: a randomized trial of 10 days penicillin vs 10 days penicillin with rifampin during the final 4 days of therapy. J Pediatr. 1985; 106:481-486.
42. Shulman ST, Gerber MA, Tanz RR, Markowitz M. Streptococcal pharyngitis: the case for penicillin therapy. Pediatr Infect Dis J. 1994;13:1-7.
43. Dajani AS, Kessler SL, Mendelson R, Uden DL, Todd WM. Cefpodoxime proxetil vs penicillin V in pediatric streptococcal pharyngitis/tonsillitis. Pediatr Infect Dis J. 1993;12:275-279.
44. Tanz RR, Poncher JR, Corydon KE, Kabat K, Yogev R, Shulman ST. Clindamycin treatment of chronic pharyngeal carriage of group A streptococci. J Pediatr. 1991;119:123-128.
45. The Meningococcal Disease Surveillance Group. Meningococcal disease: secondary attack rate and chemoprophylaxis in the United States, 1974. JAMA. 1976;235:261-265.
46. Davies HD, Low DE, Schwartz B, et al. Evaluation of short-course therapy with cefixime or rifampin for eradication of pharyngeally carried group A streptococci: the Ontario GAS Study Group. Clin Infect Dis. 1995;21:1294-1299.
47. The Meningococcal Disease Surveillance Group. Analysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis. J Infect Dis. 1976;134:201-204.
48. Auerbach SB, Schwartz B, Williams D, et al. Outbreak of invasive group A streptococcal infections in a nursing home: lessons on prevention and control. Arch Intern Med. 1992;152:1017-1022.
49. McNutt LA, Casiano-Colon AE, Coles FB, et al. Two outbreaks of primarily noninvasive group A streptococcal disease in the same nursing home, New York, 1991. Infect Control Hosp Epidemiol. 1992;13:748-751.